Gapping up
In reaction to earnings/guidance:
- HCA +5.7%, CSX +2.6%, OZK +2.5%, PG +2.1%, VMI +2% (also $400 mln share repurchase reauthorization and a 9% dividend increase), ASB +2%, HTH +1.7%, SAP +1.6%, FFBC +1.3%, PPG +0.8%
Other news:
- WISH +17.7% (authorizes new $50 mln share repurchase program)
- CANG +5.3% (authorized $50 mln new share repurchase program)
- MDXH +4.9% (received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA.)
- AMTD +3.6% (secured $93.6 mln of investment at 21.07% premium above prior day's closing price)
- LMAT +3.4% (to distribute AZYO's cardiovascular patches in the US)
- SPRY +2% (stock offering byselling shareholders)
- ASPN +1.6% (suing Korean supplier for patent infringement)
- JANX +1.6% (first patient dosed in Phase 1 trial of JANX008)
- AXTA +1.5% (in sympathy with PPG earnings)
Analyst comments:
- T +0.9% (upgraded to Buy from Hold at HSBC Securities)
